KBY Biotech Indexv0.0.34
Search
← Pipeline|Tirazumab

Tirazumab

Phase 2/3
PLU-3000
By Plurilock
Source: Trial-derived·Trials: 2
Modality
ASO
MOA
SHP2i
Target
KIF18A
Pathway
Tau
ADPKDAngelmanOvarian Ca
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
Dec 2020
→ Jun 2031
Phase 2Current
NCT03498314
1,339 pts·Ovarian Ca
2020-12→2031-06·Completed
NCT04584025
922 pts·ADPKD
2021-04→2030-02·Completed
2,261 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-02-233.9y awayPh3 Readout· ADPKD
2031-06-205.2y awayPh3 Readout· Ovarian Ca
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2030-02-23 · 3.9y away
ADPKD
Ph3 Readout
2031-06-20 · 5.2y away
Ovarian Ca
Completed|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03498314Phase 2/3Ovarian CaCompleted1339PANSS
NCT04584025Phase 2/3ADPKDCompleted922MRD
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-2191PfizerNDA/BLAGLP-1RSHP2i
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
DoxacageneSanofiApprovedPSMASHP2i
VRT-1576Vertex PharmaPhase 2/3RETSHP2i
SovafutibatinibModernaApprovedFcRnSHP2i
RiluinavolisibModernaNDA/BLAKIF18APLK4i
DaratuximabBioMarinPhase 1PRMT5SHP2i
NirafotisoranJazz PharmaPhase 2/3TROP-2SHP2i
369-4107Hansoh PharmaPhase 2TNFαSHP2i
TalatapinarofSamsung BiologicsPhase 1/2PCSK9SHP2i